How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?

Good question. This probaby means the patient will not be a long term survivor with targeted agents. The standard thing would be to switch to immunotherapy with either single agent anti PD1 or ipi+nivo combo. A more off base possibility would be to add Pembro to avoid rapid progression upon disconti...